Gilead Stock News

With a daily gain of 4.63% and an Earnings Per Share (EPS) of 4.43, Gilead Sciences Inc ( GILD , Financial) has been attracting attention in the investment community. This article aims to answer the p

Gilead Sciences (GILD) came out with quarterly earnings of $1.34 per share, missing the Zacks Consensus Estimate of $1.60 per share. This compares to earnings of $1.58 per share a year ago.

Gilead Sciences on Thursday reported lower second-quarter profit as costs from a legal settlement and sharply lower sales of its COVID-19 treatment offset another strong performance by HIV drugs.

The biotechnology sector is huge and growing. Grand View Research forecasts that the industry will reach $3.88 trillion by 2030, growing at a compound annual growth rate of 14%.

Investors' focus is likely to be on Gilead's (GILD) HIV franchise performance and oncology sales when the company reports its second-quarter 2023 results.

U.S. equities gained after better-than-expected second quarter earnings reports, with the S&P 500 rising 0.4% on Monday, July 24, 2023.

Gilead Sciences, Inc. (GILD) discontinues phase III ENHANCE study, evaluating the potential of magrolimab as a treatment for higher-risk myelodysplastic syndromes, due to futility based on a planned a

Gilead Sciences, Inc. (NASDAQ:GILD) started on the back foot on Monday after the biopharmaceutical company told investors it has discontinued its Phase 3 ENHANCE study of its investigational anti-CD4

Shares of Gilead Sciences Inc. GILD, +0.88% dropped nearly 2% in the extended session Friday after the pharma company said it has ended a late-stage trial of a treatment for a rare type of blood cance

Gilead Sciences Inc said on Friday it was stopping a late-stage trial of its blood cancer treatment following an analysis.

The Nasdaq is known for its high-flying growth stocks, and with good reason. But there's more to the index than just those aggressive names.

Vertex dominates the cystic fibrosis market and is dipping its toes in new areas. Moderna's mRNA vaccine platform could lead to major approvals in the coming years.

Gilead's (GILD) antiviral treatment Veklury (remdesivir) has now been approved for the treatment of COVID-19 patients with severe renal impairment, including those on dialysis.

Gilead is a biotech company with a recession-resistant portfolio and a reasonable valuation. Kroger is a Warren Buffett stock that produces reliable cash flows.

FOSTER CITY, Calif.--(BUSINESS WIRE)-- #Earnings--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its second quarter 2023 financial results and guidance will be released on Thursday, August